Bank Hapoalim BM trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 26.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,468 shares of the company’s stock after selling 1,971 shares during the period. Bank Hapoalim BM’s holdings in Johnson & Johnson were worth $848,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $35,000. GW&K Investment Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $35,000. Dark Forest Capital Management LP grew its stake in shares of Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares during the last quarter. Retirement Financial Solutions LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $40,000. Finally, Ruedi Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $42,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $159.06 on Tuesday. The firm’s 50-day moving average price is $160.13 and its 200-day moving average price is $161.64. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The firm has a market capitalization of $413.35 billion, a P/E ratio of 33.28, a P/E/G ratio of 2.73 and a beta of 0.55. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on JNJ. StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Atlantic Securities reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Finally, UBS Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective on the stock. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.77.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
